Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV261 Safety and PK in Healthy Volunteers
NCT07302269Phase 1Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 4'-fluorouridine in hyperuricemia and gout, sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum plasma concentration at 48 hours, Area under the curve to last measurable concentration at 48 hours and 8 more. Started Jan 2026; status: recruiting.
02
Drugs
4'-fluorouridine
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT07302269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302269.